Insider Buying: Cerecor Inc (NASDAQ:CERC) Major Shareholder Buys 28,926 Shares of Stock

Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund bought 28,926 shares of Cerecor stock in a transaction dated Friday, July 27th. The stock was acquired at an average price of $4.41 per share, with a total value of $127,563.66. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Tuesday, July 31st, Armistice Capital Master Fund bought 2,855 shares of Cerecor stock. The stock was acquired at an average price of $4.25 per share, with a total value of $12,133.75.
  • On Wednesday, July 18th, Armistice Capital Master Fund bought 30,019 shares of Cerecor stock. The stock was acquired at an average price of $4.28 per share, with a total value of $128,481.32.
  • On Monday, July 2nd, Armistice Capital Master Fund bought 18,200 shares of Cerecor stock. The stock was acquired at an average price of $4.11 per share, with a total value of $74,802.00.
  • On Wednesday, May 23rd, Armistice Capital Master Fund bought 50,000 shares of Cerecor stock. The stock was acquired at an average price of $3.78 per share, with a total value of $189,000.00.
  • On Thursday, May 17th, Armistice Capital Master Fund acquired 130,000 shares of Cerecor stock. The shares were purchased at an average price of $3.60 per share, with a total value of $468,000.00.

Shares of NASDAQ:CERC opened at $4.46 on Friday. The company has a quick ratio of 0.67, a current ratio of 0.91 and a debt-to-equity ratio of 0.59. Cerecor Inc has a 1 year low of $0.52 and a 1 year high of $5.74. The firm has a market cap of $133.06 million, a P/E ratio of 17.67 and a beta of 1.28.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings data on Friday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter. Cerecor had a return on equity of 41.38% and a net margin of 15.71%. The firm had revenue of $4.48 million for the quarter. analysts anticipate that Cerecor Inc will post -0.39 earnings per share for the current year.

Separately, TheStreet lowered Cerecor from a “c-” rating to a “d” rating in a report on Friday, June 22nd.

Large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Cerecor by 630.4% during the second quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock worth $120,000 after acquiring an additional 23,752 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Cerecor by 182.0% during the first quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock worth $135,000 after acquiring an additional 20,333 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of Cerecor during the second quarter worth $288,000. Finally, O Shaughnessy Asset Management LLC purchased a new stake in shares of Cerecor during the first quarter worth $315,000. Institutional investors and hedge funds own 53.43% of the company’s stock.

About Cerecor

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

See Also: Google Finance Portfolio

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply